We are boosting cell rejuvenation to treat currently incurable neurodegenerative and rare genetic diseases
Autophagy (from the Ancient Greek: ”self-eating”) is the cell’s main method for recycling damaged components and this process declines with age. There is compelling evidence that boosting autophagy leads to increased healthspan and lifespan, while impaired autophagy drives many serious diseases.
We are enhancing healthspan, by building an unbiased data-driven drug discovery engine
We’re letting our proprietary data guide us in new and unexpected directions to find better ways to restore autophagy. This approach allows us to uncover novel biology and gives us fundamental insights into how the cell controls this process. It’s led us very quickly to first in class, disease modifying programs which have exciting therapeutic activity.
We caught up with Senior Scientists Gabriela Vilema Enríquez and Matthew Williamson on their work within the neuroscience team at Samsara.
CMT Research Foundation and Samsara Therapeutics Partner on a Novel Therapeutic Approach for CMT1A with the Potential to Reach Clinical Trials
Hear from Nicole Mak, a Biology student at Bath University, on her year in industry with Samsara.
Michael Schlossmacher, Susan Perlman, Ed Tate and Christian Behl to help advance development of neurodegeneration and rare genetic disease therapeutics